Article Text

PDF
OC-093 A pragmatic multicentre randomised controlled trial comparing stapled haemorrhoidopexy to traditional excisional surgery for haemorrhoidal disease. the ethos trial
  1. AJ Watson1,
  2. H Bruhn2,
  3. K Macleod3,
  4. A McDonald4,
  5. G McPherson4,
  6. M Kilonzo2,
  7. J Norrie4,
  8. MA Loudon1,
  9. K McCormack4,
  10. J Wood4,
  11. JA Cook5
  1. 1Department of Surgery, NHS Highland, Inverness
  2. 2Health Economics Research Unit, University of Aberdeen, Aberdeen
  3. 3Research & Development, NHS Highland, Inverness
  4. 5Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences, University of Oxford, Oxford, UK
  5. 4Centre for Healthcare Randomised Trials (CHaRT), Health Services Research Unit, University of Aberdeen, Aberdeen

Abstract

Introduction Haemorrhoidal disease is common in all age groups from the mid-teens onwards. Approximately 25,000 procedures were performed in England during 2006/2007 on hospital day-cases or inpatients.1Current interventions include traditional excisional surgery (TH) and stapled haemorrhoidopexy (SH). Uncertainty remains about how they compare.2–6

The primary aim of eTHoS is to assess whether there is a difference between SH and TH7 for the treatment of haemorrhoidal disease (grades II, III, and IV) on patient centred quality of life profile. Treatment costs will also be examined.

Method Participants were randomly allocated to one of two study groups in equal proportion (SH or TH). Thirty-one sites from within the UK took part in the study. Patients, aged 18 year or older, with a diagnosis of circumferential haemorrhoids grade II–IV were eligible to take part. Randomisation utilised a minimisation algorithm which incorporated centre, grade of haemorrhoid (s), baseline EuroQol 5 Dimension health status questionnaire (EQ-5D) score and gender.

The primary outcome for this study is patient-centred, quality of life profile (area under the curve (AUC) derived from EQ-5D data collected at baseline, 1 week, 3 weeks, 6 weeks, 12 months and 24 months; Economic, incremental cost per quality adjusted life year (QALY) gained with QALYs were based on the responses to the EQ-5D.

A sample size of n = 338 per group was calculated to provide 90% power to detect a difference in the mean area under the quality of life curve of 0.25 standard deviations (derived from EQ-5D score measurements, with a significance level of 5%). 400 were to be randomised to each group.

Results The eTHoS trial closed for recruitment in August 2014 and is in follow-up. A total of 1129 patients were approached to take part in the trial. 777 participants were randomised (388 to TH and 389 to SH) with 7 post-randomisation exclusions from each group.

Conclusion This trial is currently the largest of its type in the world. Our results will be reported in full in October 2016 to The National Institute for Health Research.

Disclosure of interest None Declared.

References

  1. NHS Information Centre UK; http://www.hesonline.nhs.uk/servlet/ContentServer?siteID=1937&catergoryID-215

  2. Shao WJ, et al. Br J Surg. 2008;95(2):147–60

  3. Jayaraman S, et al. Dis Colon Rectum. 2007;50(9):1297–305

  4. Burch J, et al. Health Technol Assess. 2008;12(8)

  5. Thaha MA, et al. Gut 2009;58(5):668–78

  6. Shanmugam, et alet al. Colorectal Dis. 2010;12:579–86

  7. Watson, et alet al. Trials 2014;15:439

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.